TipRanks
NurExone Biologic (DE:J90)
FRANKFURT:J90
Germany Market
J90
NurExone Biologic
RESEARCH TOOLSreports

NurExone Biologic (J90) Income Statement

4 Followers

NurExone Biologic Income Statement

Last quarter (Q4 2025), NurExone Biologic's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q4, NurExone Biologic's net income was $-1.40M. See NurExone Biologic’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Mar 26Mar 25Mar 24Dec 22Mar 22
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 6.32M$ 5.01M$ 3.66M$ 7.62M$ 1.68M
Depreciation and Amortization
$ 185.00K$ 85.00K$ 33.00K$ 14.00K$ 0.00
EBITDA
$ -6.17M$ -4.94M$ -3.60M$ -8.12M$ -1.68M
Operating Income
$ -6.32M$ -5.01M$ -3.66M$ -7.62M$ -1.68M
Other Income/Expenses
$ -61.00K$ -35.00K$ 18.00K$ -550.00K$ 64.89K
Pretax Income
$ -6.38M$ -5.04M$ -3.64M$ -8.17M$ -1.62M
Net Income
$ -6.38M$ -5.04M$ -3.64M$ -8.17M$ -1.62M
Per Share Metrics
Basic EPS
$ -0.08$ -0.08$ -0.08$ -0.22$ -0.99
Diluted EPS
$ -0.08$ -0.08$ -0.08$ -0.22$ -0.99
Weighted Average Shares Outstanding
 80.02M 65.42M 44.72M 37.73M 1.65M
Weighted Average Shares Outstanding (Diluted)
 80.02M 65.42M 44.72M 37.73M 1.65M
Currency in USD

NurExone Biologic Earnings and Revenue History